Mangoceuticals (MGRX) Operating Expenses (2023 - 2026)

Mangoceuticals has disclosed Operating Expenses across 4 years of filings, most recently posting $1.1 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 79.9% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $12.2 million (down 9.96% YoY), while the FY2025 annual figure was $18.3 million, up 118.9% from the prior year.
• Operating Expenses came in at $1.1 million for Q2 2026 at Mangoceuticals, down from $3.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $7.6 million in Q3 2025 to a low of $415214.0 in Q4 2025.
• Average Operating Expenses over 4 years is $2.9 million, with a median of $2.4 million recorded in 2023.
• Year-over-year, Operating Expenses soared 312.54% in 2025 and plunged 79.9% in 2026.
• Over 4 years, Operating Expenses stood at $2.7 million in 2023, then tumbled by 35.15% to $1.8 million in 2024, then sank by 76.38% to $415214.0 in 2025, then soared by 159.45% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $1.1 million in Q2 2026, $3.2 million in Q1 2026, and $415214.0 in Q4 2025.